CLDX

Celldex Therapeutics, Inc.

Health Care Quarter ended 2026-09-30 Filed 2026-11-05

A free key covers every company here: 1,000 calls a month, no card.

What it owns, and who has a claim on it

Both columns are the same height because they are the same money, counted twice: once by what it is, once by who it belongs to.

Owns$722M
Owed & owned$72M + $649M
Assets, line by line
Cash$27M4%
Property & equipment$11M2%
Intangibles$27M4%
Other assetsincludes 3 line items this filer does not report separately$656M91%
Liabilities and equity, line by line
Accounts payable$11M2%
Other liabilitiesincludes 1 line item this filer does not report separately$61M8%
Shareholders' equity$649M90%

Not reported separately

This filer does not break these out. They are inside the totals, counted in the shaded remainder — not estimated, and not set to zero.

ReceivablesInventoryGoodwillLong-term debt

Celldex Therapeutics, Inc. (CLDX) files with the SEC as a health care company. Its most recent balance sheet puts total assets at $722M, against $72M of liabilities and $649M of equity, as at 2026-09-30. That balance sheet shrank 7.8% against 2026-06-30, when total assets were $782M. Liabilities account for 10.0% of the balance sheet and equity 90.0%, about $0.11 of liabilities for every dollar of equity. The largest single line on the asset side is Intangibles at $27M, 3.8% of total assets, followed by Cash at $27M. Its largest single liability is Accounts payable at $11M, 1.6% of the balance sheet. The figures come from a filing filed on 2026-11-05. Some line items this filer reports are not broken out separately here; the totals are complete and the difference is shown as a remainder rather than distributed across the lines that are named. Assets equal liabilities plus equity on the filed figures, so this balance sheet reconciles directly. Every figure above is as filed, taken from the most recent filing that reported it. Nothing is estimated or smoothed, and where the filing and the identity disagree the disagreement is shown rather than closed.

It is mostly owner-funded: equity is 90% of the balance sheet, borrowings and other claims the rest.

Not every line item is reported separately by this filer: receivables, inventory, goodwill, long-term debt are inside the totals rather than broken out.

The numbers behind Celldex Therapeutics, Inc.’s balance sheet

The check, written out

Assets $721,531,000 − (liabilities $72,062,000 + equity $649,469,000) = $0

Ratios

Ratios computed from this balance sheet
Liabilities to assets$72M ÷ $722M10.0%
Equity to assets$649M ÷ $722M90.0%
Liabilities to equity$72M ÷ $649M0.11×
Largest asset line: Intangibles$27M ÷ $722M3.8%
Largest liability line: Accounts payable$11M ÷ $722M1.6%

Does it balance, quarter by quarter

8 of the last 8 tested balance sheets on file reconcile as this site reads them. Each row is judged by the same check as the drawing above, and “latest filing” is the newest filing that carried that period's figures, since later filings repeat earlier periods as comparatives.

Balance sheet totals and identity result by period
Period endLatest filingAssetsLiabilitiesEquityA = L + E
2026-09-302026-11-05$722M$72M$649MBalanced
2026-06-302026-08-06$782M$68M$715MBalanced
2026-03-312026-05-07$511M$55M$456MBalanced
2025-12-312026-02-25$583M$56M$527MBalanced
2025-09-302025-11-10$648M$50M$598MBalanced
2025-06-302025-08-07$692M$37M$655MBalanced
2025-03-312025-05-08$739M$36M$703MBalanced
2024-12-312025-02-27$792M$45M$747MBalanced

Where to go from here

Ask about these numbers

Answered from the figures on this page and nothing else. Ask for something that is not here — another company, a share price, an earlier quarter — and it will tell you it is not in the filing data.

This is a language model reading the same numbers you can see. It does not predict, rate or recommend.

Learn more

Every figure here is also available as JSON — the API reference and what it costs.

Related companies

The nearest in size that file in the same sector, each drawn to the same scale.